HCW Biologics CFO Rebecca Byam Signals Confidence In The Stock, Topping Up Holdings By $160K

This article was originally published on ValueWalk

HCW Biologics

On Wednesday, the CFO of biotech firm HCW Biologics Inc (NASDAQ:HCWB), Rebecca Byam, disclosed in a US Securities and Exchange Commission filing that she purchased 66,452 shares at an average price of $2.42 a share for a total slightly above $160,000. HCW Biologics is a company that is focused on discovering and developing novel immunotherapies […]

Responses